Similarly, a retrospective analysis of the HERA trial, a phase III randomized clinical trial evaluating the efficacy of trastuzumab in HER-2 positive early-stage breast cancer, found no significant difference in LRR after PMRT in N0 patients (p = 0.96) [38]. This evidence concerns the gene ERBB2 and breast carcinoma.